A detailed history of Xponance, Inc. transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Xponance, Inc. holds 13,654 shares of BCRX stock, worth $103,770. This represents 0.0% of its overall portfolio holdings.

Number of Shares
13,654
Previous 12,980 5.19%
Holding current value
$103,770
Previous $80,000 28.75%
% of portfolio
0.0%
Previous 0.0%

Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$6.41 - $8.69 $4,320 - $5,857
674 Added 5.19%
13,654 $103,000
Q2 2024

Aug 14, 2024

BUY
$4.13 - $6.79 $6,215 - $10,218
1,505 Added 13.12%
12,980 $80,000
Q1 2024

May 13, 2024

BUY
$4.89 - $7.65 $459 - $719
94 Added 0.83%
11,475 $58,000
Q4 2023

Jan 31, 2024

BUY
$4.98 - $6.77 $906 - $1,232
182 Added 1.63%
11,381 $68,000
Q3 2023

Oct 23, 2023

BUY
$6.71 - $7.92 $704 - $831
105 Added 0.95%
11,199 $79,000
Q2 2023

Jul 13, 2023

BUY
$6.96 - $8.81 $3,389 - $4,290
487 Added 4.59%
11,094 $78,000
Q4 2022

Jan 23, 2023

BUY
$10.5 - $14.2 $1,711 - $2,314
163 Added 1.56%
10,607 $0
Q3 2022

Oct 24, 2022

BUY
$10.79 - $14.81 $3,992 - $5,479
370 Added 3.67%
10,444 $132,000
Q2 2022

Aug 02, 2022

BUY
$7.89 - $17.88 $79,483 - $180,123
10,074 New
10,074 $107,000

Others Institutions Holding BCRX

About BIOCRYST PHARMACEUTICALS INC


  • Ticker BCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,944,992
  • Market Cap $1.41B
  • Description
  • BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...
More about BCRX
Track This Portfolio

Track Xponance, Inc. Portfolio

Follow Xponance, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Xponance, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Xponance, Inc. with notifications on news.